ストックスクリーナーアプリを入手
203.73
2.26%
-4.72
アフターアワーズ：
204.11
0.38
+0.19%
前日終値:
$208.45
開ける：
$205.64
24時間の取引高:
1.71M
Relative Volume:
0.31
時価総額：
$315.94B
収益：
$58.80B
当期純損益:
$10.24B
株価収益率:
62.14
EPS:
3.2788
ネットキャッシュフロー:
$8.98B
1週間 パフォーマンス:
-0.59%
1か月 パフォーマンス:
+8.13%
6か月 パフォーマンス:
+154.06%
1年 パフォーマンス:
+167.33%
1日の値動き範囲:
$203.34
$206.30
1週間の範囲:
$202.64
$209.93
52週間の値動き範囲:
$61.24
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
203.73 | 323.26B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
LLY
Lilly Eli Co
|
1,017.97 | 992.40B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
248.56 | 598.69B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
234.26 | 410.36B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
166.87 | 321.75B | 54.72B | 14.02B | 15.32B | 7.1855 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2025-10-27 | 再開されました | Jefferies | Buy |
| 2025-10-16 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-02-13 | アップグレード | UBS | Neutral → Buy |
| 2025-02-12 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-20 | アップグレード | UBS | Sell → Neutral |
| 2024-11-06 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca Plc (AZN) 最新ニュース
AstraZeneca PLC (NASDAQ:AZN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
AstraZeneca PLC $AZN Shares Bought by US Bancorp DE - MarketBeat
Harvest Portfolios Group Inc. Sells 20,219 Shares of AstraZeneca PLC $AZN - MarketBeat
AlphaCore Capital LLC Increases Stock Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Acquired by TD Asset Management Inc - MarketBeat
Erste Asset Management GmbH Sells 29,313 Shares of AstraZeneca PLC $AZN - MarketBeat
PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race - GlobeNewswire Inc.
AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange - FinancialContent
Thornburg Investment Management Inc. Sells 24,703 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca has 'sector leading replacement power' to cope with 2030 patent cliff - Proactive Investors
AstraZeneca (AZN) prices $2bn in new fixed-rate global bond tranches - Stock Titan
AstraZeneca prices $2 bln bond offering - marketscreener.com
Primecap Management Co. CA Sells 1,342,120 Shares of AstraZeneca PLC $AZN - MarketBeat
RWA Wealth Partners LLC Purchases 6,444 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLCAstraZeneca prices a $2bn bond offering - Research Tree
AstraZeneca Prices Three-tranche Global Bond Issue Worth $2 Billion - marketscreener.com
REGAstraZeneca PLCAstraZeneca prices a $2bn bond offering - TradingView
AstraZeneca’s Soriot Rewarded With $23m Pay But Still Lags Behind US Peers - Citeline News & Insights
AstraZeneca Advances Subcutaneous Durvalumab Study, Targeting More Convenient Cancer Care - TipRanks
Astrazeneca files 2025 annual report on Form 20-F with SEC - Investing.com
Astrazeneca files 2025 annual report on Form 20-F with SEC By Investing.com - Investing.com South Africa
Compound Planning Inc. Has $2.53 Million Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Medicines: Oncology Portfolio and Pipeline - AstraZeneca
Assessing AstraZeneca (LSE:AZN) Valuation After Strong Recent Share Price Momentum - simplywall.st
[6-K] ASTRAZENECA PLC Current Report (Foreign Issuer) | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca Drug Price Challenge Falls Short In Hawaii - Law360
AstraZeneca boss Pascal Soriot nets £17.7m in pay and bonuses for 2025 - Yahoo Finance UK
AstraZeneca’s CLARITY-Gastric 02 Trial Targets New Front in Stomach Cancer - TipRanks
AstraZeneca Fails in Bid to Halt Hawaii 340B Drug Delivery Law - Bloomberg Law News
AstraZeneca publishes 2025 annual financial report and sets AGM for April - Investing.com South Africa
AstraZeneca announces board changes as Nazneen Rahman to retire in April By Investing.com - Investing.com South Africa
AstraZeneca announces board changes as Nazneen Rahman to retire in April - Investing.com
AstraZeneca (AZN) publishes 2025 Annual Report and sets 9 April 2026 AGM - Stock Titan
AstraZeneca (AZN) outlines non-executive board and committee changes - Stock Titan
AstraZeneca PLC Announces Directorate And Committee Changes, Effective April 9, 2026 - marketscreener.com
AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025 - marketscreener.com
AstraZeneca announces retirement of non-executive director Nazneen Rahman - marketscreener.com
BRIEF-AstraZeneca Announces Retirement Of Non-Executive Director Nazneen Rahman - Devdiscourse
AstraZeneca : Directorate change - marketscreener.com
Transatlantique Private Wealth LLC Takes Position in AstraZeneca PLC $AZN - MarketBeat
Zevin Asset Management LLC Sells 7,994 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Sold by Vestmark Advisory Solutions Inc. - MarketBeat
Legacy Financial Advisors Inc. Invests $1.06 Million in AstraZeneca PLC $AZN - MarketBeat
FDA Gives Green Light to AstraZeneca's All-Oral Calquence-Venetoclax Combo for CLL - StockInvest.us
Marks Group Wealth Management Inc Buys 5,896 Shares of AstraZeneca PLC $AZN - MarketBeat
Westerkirk Capital Inc. Invests $906,000 in AstraZeneca PLC $AZN - MarketBeat
Fact Check: No, AstraZeneca Vaccine Does Not Mean 'Path to Death' - Tempo.co English
AstraZeneca PLC (LON:AZN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026? - The Globe and Mail
AstraZeneca (AZN) Gains FDA Orphan Designation for Follicular Ly - GuruFocus
AstraZeneca Secures US Approval For Fixed-duration Calquence Regimen In CLL - DirectorsTalk Interviews
Astrazeneca Plc (AZN) 財務データ
収益
当期純利益
現金流量
EPS
1.04%
0.94%
大文字化:
|
ボリューム (24 時間):